Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib (HM43239) for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Contact Us

Clinical Trials

Clinical Trials

  • Overview
  • Luxeptinib for CLL & NHL
  • Luxeptinib for AML
  • Tuspetinib (HM43239) for AML
  • Expanded Access
© 2023 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap